

Cambodia

Population 2018

16 million

Estimates of TB burden ^o , 2018	Number (thousands)	Rate (per 100 000 population)
Total TB incidence	49 (27–77)	302 (169–473)
HIV-positive TB incidence	1.1 (0.59–1.7)	6.5 (3.6–10)
MDR/RR-TB incidence ^{oo}	1 (0.46–1.9)	6.4 (2.8–11)
HIV-negative TB mortality	3 (1.9–4.3)	18 (12–26)
HIV-positive TB mortality	0.38 (0.21–0.6)	2.3 (1.3–3.7)

Estimated proportion of TB cases with MDR/RR-TB, 2018

New cases	1.8% (1.2–2.8)
Previously treated cases	8.2% (4–16)

TB case notifications, 2018

Total new and relapse	28 620
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	94%
- % pulmonary	65%
- % bacteriologically confirmed ^{ooo}	53%
- % children aged 0–14 years	19%
- % women	36%
- % men	45%
Total cases notified	28 757

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2018	58% (37–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2018	7% (4–12)

TB/HIV care in new and relapse TB patients, 2018

	Number	(%)
Patients with known HIV status who are HIV-positive	580	2%
- on antiretroviral therapy	580	100%

Drug-resistant TB care, 2018

% of bacteriologically confirmed TB cases tested for rifampicin resistance ^{ooo}	
- New cases	
- Previously treated cases	
Laboratory-confirmed cases*	MDR/RR-TB: 128, XDR-TB: 0
Patients started on treatment**	MDR/RR-TB: 128, XDR-TB: 0
MDR/RR-TB cases tested for resistance to second-line drugs	125

Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2017	94%	34 238
Previously treated cases, excluding relapse, registered in 2017	79%	229
HIV-positive TB cases registered in 2017		
MDR/RR-TB cases started on second-line treatment in 2016	64%	101
XDR-TB cases started on second-line treatment in 2016		

TB preventive treatment, 2018

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	

TB financing, 2019

National TB budget (US\$ millions)	31
Funding source: 17% domestic, 23% international, 60% unfunded	

^o Ranges represent uncertainty intervals

^{oo} MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin


^{ooo} Calculated for pulmonary cases only

* Includes cases with unknown previous TB treatment history

** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)




Legend:
■ Total TB incidence
■ New and relapse TB cases notified
■ HIV-positive TB incidence

(Rate per 100 000 population per year)




Legend:
■ HIV-negative TB mortality

Notified cases by age group and sex, 2018




Legend:
■ Females ■ Males Incidence

Treatment success rate (%)



Legend:
■ New and relapse
■ Retreatment, excluding relapse
■ HIV-positive ■ MDR/RR-TB ■ XDR-TB

Total budget (US\$ millions)



Legend:
■ Unfunded
■ Funded internationally
■ Funded domestically